Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $195
Benzinga Newsdesk 15 hours ago
Analyst RatingsNewsPrice TargetHot
Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $137 to $195.
Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $137 to $195.